<i><scp>BRAF</scp></i>/<i><scp>NRAS</scp></i> wild‐type melanoma, <scp>NF</scp>1 status and sensitivity to trametinib

Abstract excerpt

Dear Editor, Despite recent advances in the management of metastatic melanoma using targeted therapies, options for patients with tumours that are BRAF and NRAS wild type remain limited (Dummer et al., 2012). BRAF/NRAS wild-type melanoma accounts for 13–26% of all melanoma cases (Hodis et al., 2012; Mar et al., 2013) and is generally characterized by a high C > T mutation burden, loss of function mutations and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cutaneous Melanoma Detection and Management
• Share to Immunotherapy and Immune Responses
• Share to Melanoma and MAPK Pathways